Article
Oncology
Dong-Dong Jia, Yanling Niu, Honglin Zhu, Sizhen Wang, Tonghui Ma, Tao Li
Summary: This study investigated the impact of prior IFN-alpha therapy on subsequent PD-1 blockade in melanoma patients. The findings showed that prior PEG-IFN-alpha therapy enhanced the efficacy of adjuvant pembrolizumab, reducing recurrence rates and prolonging recurrence-free survival. These results suggest that prior PEG-IFN-alpha treatment could be beneficial in designing combination or sequential immunotherapy for melanoma patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Dermatology
Jingjing Li, Jiuhong Wang, Dandan Li, Xizhi Wen, Ya Ding, Xing Liu, Hang Jiang, Fuxue Huang, Xiaoshi Zhang
Summary: This retrospective study found that adjuvant PD-1 inhibitors provided significantly longer RFS and DMFS in Chinese patients with stage IIIB/C cutaneous melanoma compared to high-dose interferon alpha-2b (HDI), but there was no significant advantage observed in patients with acral melanoma.
DERMATOLOGIC THERAPY
(2021)
Article
Oncology
Yana G. Najjar, Dustin McCurry, Huang Lin, Yan Lin, Yan Zang, Diwakar Davar, Arivarasan Karunamurthy, Joseph J. Drabick, Rogerio I. Neves, Lisa H. Butterfield, Marc S. Ernstoff, Igor Puzanov, Joseph J. Skitzki, Jennifer Bordeaux, IlaSri B. Summit, Jehovana O. Bender, Ju Young Kim, Beiru Chen, Ghanashyam Sarikonda, Anil Pahuja, Jennifer Tsau, Zeni Alfonso, Christian Laing, James F. Pingpank, Matthew P. Holtzman, Cindy Sander, Amy Rose, Hassane M. Zarour, John M. Kirkwood, Ahmad A. Tarhini
Summary: Neoadjuvant concurrent HDI and pembrolizumab therapy showed promising clinical activity in resectable advanced melanoma patients, despite high rates of treatment discontinuation. Pathologic complete response was identified as a prognostic indicator.
CLINICAL CANCER RESEARCH
(2021)
Article
Gastroenterology & Hepatology
Seng Gee Lim, Wei Lyn Yang, Jing Hieng Ngu, Jason Chang, Jessica Tan, Taufique Ahmed, Yock Young Dan, Kieron Lim, Yin Mei Lee, Guan Huei Lee, Poh Seng Tan, Khin Lay Wai, Wah Wah Phyo, Htet Htet Toe Wai Khine, Chris Lee, Amy Tay, Edwin Chan
Summary: For patients with chronic hepatitis B (CHB), switching to or adding peginterferon to nucleoside analogues (NA) is more effective than continuing NA. Adding peginterferon has better safety and similar efficacy compared to switching.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Oncology
Daniel Thomas, Danielle M. Bello
Summary: Surgical resection is the main treatment for early cutaneous melanoma, but some patients are at risk of relapse, especially those with high-risk features. Immunotherapy targeting checkpoint inhibitors has been shown to improve recurrence-free survival in node-positive melanoma patients.
JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Norma E. Farrow, Eda K. Holl, Jeanne Jung, Junheng Gao, Sin-Ho Jung, Rami N. Al-Rohil, Maria A. Selim, Paul J. Mosca, David W. Ollila, Scott J. Antonia, Douglas S. Tyler, Smita K. Nair, Georgia M. Beasley
Summary: The gene expression profiles of sentinel lymph nodes are associated with melanoma recurrence and can potentially identify patients as high or low risk for recurrence regardless of sentinel lymph node status, enhancing patient selection for adjuvant therapy.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
R. Dummer, D. E. Gyorki, J. Hyngstrom, A. C. Berger, R. Conry, L. Demidov, A. Sharma, S. A. Treichel, H. Radcliffe, K. S. Gorski, A. Anderson, E. Chan, M. Faries, M. I. Ross
Summary: The study found that intralesional injection of an oncolytic virus prior to surgery is clinically beneficial for patients with locally advanced, resectable melanoma, leading to improved recurrence-free survival.
Article
Infectious Diseases
Ying-Zi Ye, Ya-Lan Dou, Jian-Hua Hao, Li Zhou, Ai-Wei Lin, Shao-Ning Wang, Ji-Kui Deng, Min Lei, Ru-Ping Luo, Yi-Nan Liao, Yan Chen, Yuan-Yuan Long, Bi-Quan Chen, Zhi Yang, Lu Gan, Guang-Min Nong, Wei-Li Yan, Hui Yu
Summary: The study found that interferon alpha-2b spray showed better efficacy in treating acute herpangina in children compared to Ribavirin. Additionally, it was deemed safe for use with no adverse reactions reported.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Review
Ophthalmology
Pau Cid-Bertomeu, Valentin Huerva
Summary: Primary acquired melanosis (PAM) is a conjunctival pigmentation that can lead to conjunctival melanoma (CM). Surgical excision is the preferred treatment, but topical chemotherapy with interferon alpha 2b (IFN-a2b) is also an important option. IFN-a2b has shown efficacy in treating PAM and CM, with low toxicity.
SURVEY OF OPHTHALMOLOGY
(2022)
Article
Health Care Sciences & Services
Laurie E. McLouth, Yue Zheng, Stephanie Smith, F. Stephen Hodi, Uma N. Rao, Gary Cohen, Thomas T. Amatruda, Shaker R. Dakhil, Brendan D. Curti, Ibrahim Nakhoul, Sreenivasa R. Chandana, Charles L. Bane, David E. Marinier, Sandra J. Lee, Vernon K. Sondak, John M. Kirkwood, Ahmad A. Tarhini, Lynne Wagner
Summary: This study compared the health-related quality of life (HRQoL), gastrointestinal (GI) symptoms, and treatment-specific physical and cognitive/emotional symptoms between ipilimumab and high-dose interferon (HDI) in patients with resected high-risk melanoma. The results showed that ipilimumab patients had better HRQoL, fewer physical and cognitive/emotional concerns, but worse GI symptoms compared to HDI.
QUALITY OF LIFE RESEARCH
(2023)
Article
Oncology
Mathieu F. Bakhoum, Ellis J. Curtis, Michael H. Goldbaum, Paul S. Mischel
Summary: Assessment of BAP1 methylation is an accurate and readily clinically actionable assay to identify high-risk uveal melanoma patients.
NPJ PRECISION ONCOLOGY
(2021)
Article
Oncology
Yunteng Wu, Dongliang Wei, Guoxin Ren, Wei Guo
Summary: In this study, it was found that invasion level and tumor thickness were independent prognostic factors for oral mucosal melanoma. Chemotherapy plus anti-PD-1 agents appeared to be the preferred adjuvant therapy for oral mucosal melanoma, as it was safer and more tolerable than HDI and significantly improved overall survival and progression-free survival.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Oncology
F. Dimitriou, G. V. Long, A. M. Menzies
Summary: This review discusses the latest clinical trial data, current treatment landscape, and future progress for the management of resected stage IIIB-IIID melanoma. Adjuvant therapy with immunotherapy or targeted therapy is recommended for improving recurrence-free survival in high-risk melanoma patients.
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
B. Lian, L. Si, Z. H. Chi, X. N. Sheng, Y. Kong, X. Wang, H. Tian, K. Li, L. L. Mao, X. Bai, B. X. Tang, X. Q. Yan, S. M. Li, L. Zhou, J. Dai, X. W. Tang, F. W. Ran, S. Yao, J. Guo, C. L. Cui
Summary: This study compared the adjuvant therapy of toripalimab and high-dose interferon-a2b in resected mucosal melanoma patients. The results showed similar relapse-free survival (RFS) in both groups, but toripalimab had a more favorable safety profile. Therefore, toripalimab may be a better treatment option for these patients.
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Andrew Bottomley, Corneel Coens, Justyna Mierzynska, Christian U. Blank, Mario Mandala, Georgina Long, Victoria G. Atkinson, Stephane Dalle, Andrew M. Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, Susana Puig, Paolo A. Ascierto, James Larkin, Paul C. Lorigan, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus J. M. van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert, Alexander M. M. Eggermont
Summary: The study showed that adjuvant pembrolizumab does not result in a clinically significant decrease in health-related quality of life (HRQOL) compared with placebo in patients with resected, high-risk stage III melanoma. These results support the use of adjuvant pembrolizumab in this setting.
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)